布里瓦拉作为发育性脑病变的儿童的附加疗法:一项对42名患者的研究
Roberto H Caraballo1, Gabriela Reyes1, Santiago Chacón2
1Department of Neurology, Juan P Garrahan Hospital, Buenos Aires, Argentina.
Epilepsy & behavior : E&B
|December 9, 2023
概括
布里瓦拉 (BRV) 有效地减少了发育性脑病变 (DEE) 的儿童的发作,超过70%的儿童出现了显著的改善. 这种附加疗法在儿科患者中证明了安全性和耐受性.
科学领域:
- 儿科神经学 儿科神经学
- 发病学 (Epileptology) 是一个专业的学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 发育性脑病变 (DEE) 是儿童发作的严重综合征.
- 耐治疗的DEE在儿科神经病学中带来了重大挑战.
- 布里瓦拉 (BRV) 是一种抗药,具有独特的药理学特征.
研究的目的:
- 评估布里瓦拉 (BRV) 作为DEE儿科患者的附加治疗的疗效和安全性.
- 评估BRV在治疗耐药病例中的有效性.
- 探索BRV在患有特定伴随性疾病 (如行为障碍) 的患者中的实用性.
主要方法:
- 在阿根廷的四个中心对42名患有DEE的儿科患者的医疗记录进行了回顾性分析.
- 患者在2021年1月至2023年7月期间接受了BRV作为附加疗法.
- 收集的数据包括发作频率,EEG异常和不良事件.
主要成果:
- 在62.1%的患者 (>50%的减少) 观察到发作频率显著减少,23.8%的患者经历了25-50%的减少.
- 三名患者 (9.5%) 实现了无性发作,而响应者中的间脉脑电图异常得到改善.
- 副作用 (昏昏欲睡,易怒,食欲下降) 是轻微的,在大多数情况下不会导致停止治疗.
结论:
- 布里瓦拉是一种有效且耐受性良好的补充治疗,用于患有DEE的儿科患者.
- 对于有行为障碍的患者,即使没有先前的 levetiracetam (LEV) 治疗,也可以考虑 BRV.
- 这项研究支持BRV作为一种有价值的治疗选择,用于治疗儿童难以治疗的.
关键词:
布里瓦拉塞坦 (Brivaracetam) 是一种发展发展发展 发展发展性脑病变 (Epileptic Encephalopathies) 是一种性脑病变 (Epileptic Encephalopathies) 是一种性脑病变 (epileptic encephalopathies) 是一种性脑病变 (epileptic encephalopathies) 是一种性脑病变 (epileptic encephalopathies) 是一种性脑病变 (epileptic encephalopathies) 是一种性脑病变.焦点和一般化的焦点和一般化.发作 在发作.更多相关视频
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
20.4K
09:29Preparation and Implantation of Electrodes for Electrically Kindling VGAT-Cre Mice to Generate a Model for Temporal Lobe Epilepsy
Published on: August 17, 2021
2.4K
相关概念视频
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
310
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
310
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
413
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
413
01:14Antiepileptic Drugs: Glutamate Antagonists
376
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
376
01:20Antiepileptic Drugs: Potassium Channel Activators
184
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
184
01:08Antiepileptic Drugs: Sodium Channel Blockers
585
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
585
01:17Antiepileptic Drugs: Calcium Channel Blockers
412
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
412